S1 Table Acute GVHD by site; S2 Table. Chronic GVHD by site.

Ramalingam, Sendhilnathan; Siamakpour-Reihani, Sharareh; Bohannan, Lauren; Ren, Yi; Sibley, Alexander; Sheng, Jeff; Ma, Li; Nixon, Andrew B.; Lyu, Jing; Parker, Daniel C.; Bain, James; Muehlbauer, Michael; Ilkayeva, Olga; Kraus, Virginia Byers; Huebner, Janet L.; Spitzer, Thomas; Brown, Jami; Peled, Jonathan U.; van den Brink, Marcel; Gomes, Antonio; Choi, Taewoong; Gasparetto, Cristina; Horwitz, Mitchell; Long, Gwynn; Lopez, Richard; Rizzieri, David; Sarantopoulos, Stefanie; Chao, Nelson; Sung, Anthony D.

doi:10.1371/journal.pone.0252995.s002

pone.0252995.s002.docx (800.54 kB)

S1 Table Acute GVHD by site; S2 Table. Chronic GVHD by site.

journal contribution

posted on 2021-06-25, 17:31 authored by Sendhilnathan Ramalingam, Sharareh Siamakpour-Reihani, Lauren Bohannan, Yi Ren, Alexander Sibley, Jeff Sheng, Li Ma, Andrew B. Nixon, Jing Lyu, Daniel C. Parker, James Bain, Michael Muehlbauer, Olga Ilkayeva, Virginia Byers Kraus, Janet L. Huebner, Thomas Spitzer, Jami Brown, Jonathan U. Peled, Marcel van den Brink, Antonio Gomes, Taewoong Choi, Cristina Gasparetto, Mitchell Horwitz, Gwynn Long, Richard Lopez, David Rizzieri, Stefanie Sarantopoulos, Nelson Chao, Anthony D. Sung

*n = 25 is adjustment for one missing value; S3 Table. All toxicities with CTCAE frequency by treatment group. Percentages adjusted for missing values; S4 Table. Model predicting Shannon diversity incorporating anaerobic antibiotic coverage; S5 Table. Model predicting Shannon diversity incorporating febrile neutropenia; S6A Table. Pasireotide group inflammatory changes baseline to day 14 median/range followed by significance testing (54 plex panel); S6B Table. Pasireotide group inflammatory changes baseline to day 14 median/range followed by significance testing (Pepper panel); S7A Table. Pasireotide group inflammatory overall survival correlations for baseline and ratio of change from baseline to day 14 (54 plex panel); S7B Table. Pasireotide group inflammatory overall survival correlations for baseline and ratio of change from baseline to day 14 (Pepper panel); S8A Table. Pasireotide group inflammatory aGVHD correlations (54-plex panel); S8B Table. Pasireotide group inflammatory aGVHD correlations (Pepper panel); S9A Table. Pasireotide group inflammatory cGVHD correlations (54-plex panel); S9B Table. Pasireotide group inflammatory cGVHD correlations (Pepper panel); S10A Table. Pasireotide group inflammatory TRM correlations (54-plex panel); S10B Table: Pasireotide group inflammatory TRM correlations (Pepper panel); S11 Table. Pasireotide group metabolomics change from baseline to D14, median/range followed by significance testing. Conventional-C, Amino Acid-AA, Acylcarnitines-AC; S12 Table. Pasireotide group metabolomics correlation to overall survival Conventional-C, Amino Acid-AA, Acylcarnitines-AC; S13 Table. Pasireotide group metabolomics correlation to aGVHD Conventional-C, Amino Acid-AA, Acylcarnitines-AC; S14 Table. Pasireotide group metabolomics correlation to cGVHD Conventional-C, Amino Acid-AA, Acylcarnitines-AC; S15 Table. Pasireotide group metabolomics correlation to TRM Conventional-C, Amino Acid-AA, Acylcarnitines-AC.

(DOCX)